Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02606487|
Recruitment Status : Completed
First Posted : November 17, 2015
Last Update Posted : October 4, 2018
|Condition or disease|
Cystic fibrosis (CF) is one of the most common genetic diseases affecting children and young adults . Lung disease is the primary cause of morbidity and mortality in these patients and sensitive markers of lung disease in CF are important for directing therapy in these patients.
LCI, measured by multiple breath washout (MBW), has been shown to be more sensitive than traditional pulmonary function tests (PFTs) for assessing the treatment effect of novel therapies in CF patients [2,3]. However, LCI provides no information regarding the spatial distribution of ventilation inhomogeneity within the lungs and improvements in mucus plugging of poorly ventilated regions can paradoxically worsen the LCI [4,5]. Thus an imaging technique that can capture regional changes in the distribution of ventilation might be better suited than LCI to detect treatment effects and could also help to better define the utility of LCI as a clinical tool.
Xe-MRI is a safe, non-ionizing modality for imaging the lungs, providing an accurate spatial representation of ventilation inhomogeneity . Xe-MRI has been shown to be effective in imaging of adult patients with chronic obstructive pulmonary disease (COPD) and CF  however, there are no published studies using Xe-MRI in children.
The hypothesis of this study is that Xe-MRI and LCI will provide complimentary information when quantifying ventilation inhomogeneity in CF lung disease and that Xe-MRI will be able to define patients in whom LCI fails to capture positive effects of treatment. The ultimate goal is to develop more sensitive tools for longitudinal monitoring to direct the clinical care of CF patients in the future.
To accomplish this, the investigators will compare the ability of Xe-MRI and LCI to detect changes in ventilation inhomogeneity in patients with CF before and after treatment for a pulmonary exacerbation, a common pulmonary complication of CF.
|Study Type :||Observational|
|Actual Enrollment :||21 participants|
|Official Title:||Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations|
|Study Start Date :||November 2015|
|Actual Primary Completion Date :||November 2017|
|Actual Study Completion Date :||November 2017|
CF pulmonary exacerbation group
Patients with cystic fibrosis admitted for inpatient treatment of a pulmonary exacerbation
- Ventilation Defect Percentage (VDP) [ Time Frame: Pre-treatment ]VDP within 48h of initiation of inpatient treatment
- Ventilation Defect Percentage (VDP) [ Time Frame: Post-treatment - within 48h of completion of inpatient treatment ]VDP within 48h of completion of inpatient treatment
- Lung Clearance Index (LCI) [ Time Frame: Pre-treatment ]LCI within 48h of initiation of inpatient treatment
- Lung Clearance Index (LCI) [ Time Frame: Post-treatment - within 48h of completion of inpatient treatment ]LCI within 48h of completion of inpatient treatment
- Pulmonary function tests (PFTs) [ Time Frame: Pre-treatment ]PFTs within 48h of initiation of inpatient treatment
- Pulmonary function tests (PFTs) [ Time Frame: Post-treatment - within 48h of completion of inpatient treatment ]PFTs within 48h of completion of inpatient treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02606487
|The Hospital for Sick Children|
|Toronto, Ontario, Canada, M5G 1X8|
|Principal Investigator:||Felix Ratjen, MD PhD||The Hospital for Sick Children|